Ginkgo Biloba for Childhood Vitiligo: Evidence Gap and Clinical Guidance

Evidence Status

No randomized controlled trials evaluate ginkgo biloba for vitiligo in children. Adult data are limited to small open-label studies (e.g., 40–80 mg TID of standardized extract EGb 761) showing modest stabilization/repigmentation in some, but methodological flaws limit conclusions.

Potential Mechanisms (Preclinical)

  • Antioxidant: scavenges ROS, upregulates SOD, catalase.
  • Immunomodulatory: inhibits NF-κB, reduces TNF-α, IL-1β.
  • Platelet-activating factor (PAF) antagonism: may improve microcirculation.

Safety Concerns in Children

  • Bleeding risk (PAF inhibition) – caution with trauma, surgery, anticoagulants.
  • Seizure threshold lowering – avoid in seizure disorders.
  • Drug interactions: CYP2C19, CYP3A4 substrates (e.g., valproate, omeprazole).
  • Quality control: supplement ≠ pharmaceutical grade; variable ginkgolide content.

Clinical Recommendation

  1. First-line: Topical tacrolimus/pimecrolimus ± NB-UVB (evidence-based, safe in children).
  2. Do not use ginkgo as monotherapy.
  3. If parents insist on complementary approach: discuss with pediatric dermatologist, use standardized EGb 761 product, monitor for bleeding/bruising, limit duration (e.g., 3-month trial with photo-documentation).
  4. Ensure adequate vitamin D, zinc, copper, B12 – test and supplement if deficient.

Bottom line: Ginkgo biloba is not a substitute for evidence-based vitiligo treatment in children. Safety and efficacy are unproven.

Pediatrics - Related Articles